申请人:Takeda Chemical Industries, Ltd.
公开号:US04548932A1
公开(公告)日:1985-10-22
Novel 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives of the formula ##STR1## [wherein R.sup.1 and R.sup.2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy, or both jointly form tri- or tetramethylene; R.sup.3 is hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl; R.sup.4 is hydrogen, optionally substituted alkyl, optionally substituted aralkyl or optionally substituted cycloalkylalkyl; Y is a carboxyl group which may be esterified or amidated; m is 1 or 2] and salts thereof. These compounds and salts thereof exhibits inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of circulatory diseases (e.g. hypertension, cardiopathy, cerebral apoploxy).
化合物及其盐,其结构式为##STR1##[其中,R.sup.1和R.sup.2独立地为氢、卤素、三氟甲基、较低的烷基或较低的烷氧基,或共同形成三亚甲基或四亚甲基; R.sup.3为氢、可选取代的较低烷基或可选取代的芳基烷基; R.sup.4为氢、可选取代的烷基、可选取代的芳基烷基或可选取代的环烷基烷基; Y为羧基,可以酯化或酰胺化; m为1或2]。这些化合物及其盐表现出对血管紧张素转换酶等的抑制活性,因此具有作为循环疾病(如高血压、心脏病、脑中风)的诊断、预防和治疗剂的价值。